Gilead Sciences, the leading maker of drugs for HIV and hepatitis C, is making a gutsy move into the cutting edge of cancer treatment, spending $11.9 billion in cash to buy Kite Pharma, developer of a treatment that attacks tumors by genetically modifying patients’ own white blood cells.
from Forbes Real Time //www.forbes.com/sites/matthewherper/2017/08/28/gilead-kite-a-breakthrough-a-12-billion-deal-another-expensive-drug/
via IFTTT
No comments:
Post a Comment